ArticleJournal of clinical microbiology1998
Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates.
Article in Journal of clinical microbiology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 40 citations in OpenAlex.
- Distribution of ganciclovir in the porcine central nervous system.Antimicrobial agents and chemotherapy · 2025Article
- Antiviral Activities of Quercetin and Isoquercitrin Against Human Herpesviruses.Molecules (Basel, Switzerland) · 2020Article
- Use of time-saving flow cytometry for rapid determination of resistance of human cytomegalovirus to ganciclovir.Journal of clinical microbiology · 2005Article
- Human cytomegalovirus resistance to antiviral drugs.Antimicrobial agents and chemotherapy · 2005Review
- Use of a single monoclonal antibody to determine the susceptibilities of herpes simplex virus type 1 and type 2 clinical isolates to acyclovir.Clinical and diagnostic laboratory immunology · 2002Article
- Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94.Clinical and diagnostic laboratory immunology · 2001Article
- Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir.Antimicrobial agents and chemotherapy · 2001Article
- Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing.Antimicrobial agents and chemotherapy · 2001Article
- Applications of flow cytometry to clinical microbiology.Clinical microbiology reviews · 2000Review
- New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.Clinical microbiology reviews · 2000Review
- Resistance of human cytomegalovirus to antiviral drugs.Clinical microbiology reviews · 1999Review
- Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates.Antimicrobial agents and chemotherapy · 1998Article
- Drug-resistant herpesviruses: should we look for them?European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 1 country.
Funding
Abstract
A flow cytometric assay has been developed for the measurement of susceptibilities to ganciclovir of laboratory strains and clinical isolates of human cytomegalovirus (HCMV). The assay uses fluorochrome-labeled monoclonal antibodies to HCMV immediate-early and late antigens to identify HCMV-infected cells and flow cytometry to detect and quantitate the number of antigen-positive cells. By this assay, the 50 and 90% inhibitory concentrations (IC50 and IC90, respectively) of ganciclovir for the AD169 strain of HCMV were 1.7 and 9.2 microM, respectively, and the IC50 for the ganciclovir-resistant D6/3/1 derivative of the AD169 strain was greater than 12 microM. The ganciclovir susceptibilities of 17 HCMV clinical isolates were also determined by flow cytometric analysis of the effect of ganciclovir on late-antigen synthesis in HCMV-infected cells. The average IC50 of ganciclovir for drug-sensitive HCMV clinical isolates was 3.79 microM (+/-2.60). The plaque-reduction assay for these clinical isolates yielded an average IC50 of 2.80 microM (+/-1.46). Comparison of the results of the flow cytometry assays with those obtained from the plaque-reduction assays demonstrated acceptable bias and precision. Flow cytometric and plaque-reduction analysis of cells infected with ganciclovir-resistant clinical isolates failed to show a reduction in the percentage of late-antigen-positive cells or PFU, even at 96 microM ganciclovir. The flow cytometric assay for determining ganciclovir susceptibility of HCMV is quantitative, and objective, and potentially automatable, and its results are reproducible among laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.